Kolon TissueGene (950160) Q3 2025 earnings summary

Executive summary

• Focus on cell and gene therapy platform TG-C, targeting osteoarthritis and related degenerative diseases, with U.S. Phase 3 clinical trials completed for knee OA and pipeline expansion into hip OA and DDD.

• Revenue primarily from health & beauty distribution and licensing, with TG-C not yet commercialized.

• Significant R&D investment, ongoing partnerships, and robust patent portfolio support future growth.

Financial highlights

• 2025 Q3 revenue: $3.04M (down from $3.72M in 2024 Q3); operating loss: $(10.14)M (improved from $(16.13)M in 2024 Q3).

• Net loss for 2025 Q3: $(48.60)M, EPS $(2.97); cash and equivalents: $71.6M.

• R&D expenses: $55.7M YTD (1,831% of sales); accumulated deficit: $(348.98)M.

• Equity: $131.5M; total assets: $290.2M; debt ratio: 66.3%.

Outlook and guidance

• Plans to file for FDA BLA after 2-year follow-up of Phase 3 knee OA trial; commercialization targeted post-approval.

• Pipeline expansion into hip OA (Phase 2 approved) and DDD (Phase 1 approved); long-term plans for rheumatoid arthritis and animal health.

• Continued focus on R&D and strategic partnerships for global market entry.